唐氏综合征成人与儿童接种SARS-CoV-2疫苗后抗体浓度及功能随年龄下降
该前瞻性研究纳入215名唐氏综合征成人和93名健康对照成人,以及唐氏综合征儿童,检测基础免疫和加强免疫后的抗体浓度及中和滴度。结果显示唐氏综合征患者抗体浓度和中和能力均低于健康对照,且抗体浓度随年龄下降,仅在唐氏综合征中显著。青少年唐氏综合征患者抗体浓度最高,而12岁以下儿童较低。
要点
- 唐氏综合征成人基础免疫后抗S抗体浓度低于健康对照。
- 唐氏综合征患者抗体浓度随年龄下降,健康对照无此趋势。
- 加强免疫可提高抗体浓度,但唐氏综合征仍低于健康对照。
核心结论
- 唐氏综合征患者接种SARS-CoV-2疫苗后抗体浓度和血清中和能力低于健康对照,且疫苗应答缺陷随年龄增长而加重。
研究设计与样本
- 前瞻性研究纳入215名唐氏综合征成人、93名健康对照成人及唐氏综合征儿童,检测基础免疫和加强免疫后的抗体浓度及基础免疫后的中和滴度。
主要发现
- 基础免疫后唐氏综合征成人抗S抗体浓度低于健康对照:mRNA疫苗1286 BAU/mL vs 2355 BAU/mL,p<0.001;载体疫苗361 BAU/mL vs 592 BAU/mL,p<0.01。
- 仅在唐氏综合征中抗S抗体浓度随年龄下降(相关系数-0.61,p<0.001)。
- 唐氏综合征青少年(12-17岁)抗S抗体浓度最高(3286 BAU/mL),12岁以下儿童较低(1424 BAU/mL,p<0.01)。
- 加强免疫后唐氏综合征和健康对照抗体浓度均升高,但唐氏综合征仍较低,与基础疫苗类型无关。
- 唐氏综合征成人血清中和滴度低于健康对照:mRNA疫苗ID50 120 vs 336,p<0.001;载体疫苗ID50 51 vs 95,p<0.01。
临床怎么用
- 唐氏综合征患者需考虑年龄特异性的免疫策略,尤其关注年长成人和12岁以下儿童。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Individuals with Down syndrome (DS) have an altered immune system, highlighted by increased illness and mortality during the SARS-CoV-2 pandemic. We previously showed decreased antibody concentrations after primary SARS-CoV-2 vaccination in DS adults. We prospectively studied antibody responses and functionality after SARS-CoV-2 primary and booster vaccination in adults and children with DS. METHODS: We measured antibody concentrations for anti-S and anti-RBD following primary and booster vaccination and virus neutralizing titers (ID50) after primary vaccination. Adults with DS (N = 215) or healthy controls (HC, N = 93), received 2 primary doses of mRNA-based (BNT162b2/mRNA-1273) or vector-based (ChAdOx1) vaccines. Children received mRNA-based vaccines. Booster vaccination was mRNA-based. RESULTS: A rise in antibody concentrations was seen in all participants, but DS had lower anti-S antibody concentrations than HC after primary mRNA (1286 BAU/mL, vs. 2355 BAU/mL, p < 0.001) or vector (361 BAU/mL, vs. 592 BAU/mL p < 0.01) vaccination. Only in DS, anti-S concentrations declined with age (correlation-coefficient - 0.61, p < 0.001). Amongst children with DS, teenagers (12-17 years) showed highest anti-S concentrations (3286 BAU/mL), children (<12 years) had lower concentrations compared with teenagers (1424 BAU/mL, p < 0.01). Booster vaccination increased anti-S concentrations in DS and HC at all ages. However, lower concentrations in DS compared with HC remained, regardless of primary vaccine type (mRNA/vector). Anti-RBD antibodies showed similar results to anti-S. Serum neutralization was lower in DS adults compared with HC for mRNA (ID50 120 vs. ID50 336, p < 0.001) and vector (ID50 51 vs. ID50 95 p < 0.01) vaccination. CONCLUSION: This is the first vaccine immunology study in DS including both children and adults. Although all participants showed a rise in antibody concentrations, decreased antibody concentrations and serum neutralization after primary and booster SARS-CoV-2 vaccination were seen in individuals with DS compared with HC. Vaccine response defects in DS were age dependent, increasing with age. Teenagers with DS had the highest antibody concentrations while children <12 years had significantly lower concentrations. Our findings highlight the need for a tailored, age-specific immunization strategy in DS. CLINICAL TRIAL REGISTRATION: NCT05145348.
引用
- Streng BMM, Hensen LCM, Delemarre EM, et al. Antibody concentration and function following SARS-CoV-2 vaccination decrease with age in adults and children with Down syndrome. Vaccine. 2025. PMID: 41447779. doi:10.1016/j.vaccine.2025.128079
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。